Clopidogrel response in essential thrombocythemia
Part of Blood & lymphatic clinical trials.
This study is looking at how well clopidogrel works in people with essential thrombocythemia (ET). Clopidogrel is a medicine that helps prevent blood clots, and this trial will measure if your body responds to it, which can help your doctor decide on the best treatment for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with essential thrombocythemia (ET), a blood condition where your body makes too many platelets.
- You have been taking clopidogrel 75 mg every day for at least 3 weeks as a blood thinner to prevent clots.
- Your platelet count is not extremely high—less than 1,000,000 per microliter (your doctor can check this).
- You are not taking anticoagulants (like warfarin) or other antiplatelet drugs (like aspirin), and you don't regularly use painkillers like ibuprofen or steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
This trial tests a new injectable medicine (Peginterferon α-2b) for people with essential thrombocythemia (ET) whose disease is not controlled by hydroxyurea (HU) or who cannot tolerate HU. It aims to help lower high platelet counts and reduce the risk of clots or bleeding.
This study tests a new drug called INCA033989 for people with a high-risk form of essential thrombocythemia (a blood disorder causing too many platelets) who have a specific genetic change called mutCALR. The trial compares this new drug to the best currently available treatments.
This trial tests a daily pill called STP938 (dencatistat) for people with high-risk essential thrombocythemia (ET) who cannot take or have stopped responding to hydroxycarbamide. The goal is to see if STP938 can safely lower your platelet count and control the condition.
This trial looks at whether using clopidogrel by itself (without aspirin) works for people after a new drug-eluting stent, based on a blood test of how your body processes the drug. It may help reduce “extra blood-thinning” if you have a certain genetic type that responds well to clopidogrel.
This study looks at whether a blood test can show how well clopidogrel works for you after a stent is placed in a narrowed brain artery. It aims to find out if people who don't respond well to clopidogrel have a higher chance of another stroke.
Hear when a new Essential Thrombocythemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.